MiRNA-19 Promotes Non-small-cell Lung Cancer Cell Proliferation Via Inhibiting CBX7 Expression

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Dec 26

PMID 30584339

Citations 20

Authors

Xiaogang Peng

Li Guan

Baoan Gao

Affiliations

Soon will be listed here.

Abstract

Background: miR-19 is a critical carcinogenic miRNA that participates in important biological processes of human malignancies. CBX7 plays a key role in lung cancer development and progression. In the present study, for the first time, we investigated the correlation between miR-19 and CBX7 in non-small-cell lung cancer (NSCLC).

Methods: miR-19 expression in NSCLC tissues and lung cancer cell lines was detected using quantitative reverse transcriptase PCR (qRT-PCR). Luciferase reporter assay, qRT-PCR, Western blot, and immunohistochemical assay were conducted to identify the target reaction of miR-19 and CBX7. Moreover, the influence of miR-19 on lung cancer cell proliferation, migration, and invasion was studied including cell counting kit-8 assay, scratch assay, transwell assay, flow cytometry assay, and staining assays.

Results: miR-19 was overexpressed in NSCLC tissues and lung cancer cell lines. Luciferase reporter assay demonstrated that miR-19 could inhibit CBX7 expression via binding to the 3'-UTR of CBX7. Furthermore, miR-19 remarkably decreased CBX7 protein and mRNA expression. Additionally, overexpression of miR-19 could significantly enhance lung cancer cell proliferation and migration.

Conclusion: miR-19 functions as a tumor accelerator promoting lung cancer cell proliferation through targeting CBX7 and inhibiting its expression.

Citing Articles

miR-224-5p Suppresses Non-Small Cell Lung Cancer via IL6ST-Mediated Regulation of the JAK2/STAT3 Pathway.

Tian J, He Y, Zhang Z, Zhu Y, Ren H, Zhang L Thorac Cancer. 2025; 16(2):e15516.

PMID: 39840666 PMC: 11751714. DOI: 10.1111/1759-7714.15516.

Decoding the interaction between miR-19a and CBX7 focusing on the implications for tumor suppression in cancer therapy.

Zabeti Touchaei A, Vahidi S, Samadani A Med Oncol. 2023; 41(1):21.

PMID: 38112798 DOI: 10.1007/s12032-023-02251-y.

CBX7 is involved in the progression of cervical cancer through the ITGβ3/TGFβ1/AKT pathway.

Tian P, Deng J, Ma C, Miershali A, Maimaitirexiati G, Yan Q Oncol Lett. 2023; 27(1):14.

PMID: 38028179 PMC: 10664064. DOI: 10.3892/ol.2023.14147.

CBX4 deletion promotes tumorigenesis under Kras background by inducing genomic instability.

Chen F, Hou W, Yu X, Wu J, Li Z, Xu J Signal Transduct Target Ther. 2023; 8(1):343.

PMID: 37696812 PMC: 10495400. DOI: 10.1038/s41392-023-01623-0.

miR-19-3p Targets PTEN to Regulate Cervical Cancer Cell Proliferation, Invasion, and Autophagy.

Wang W, Liu L, Tian Y Genet Res (Camb). 2023; 2023:4784500.

PMID: 36908850 PMC: 10005872. DOI: 10.1155/2023/4784500.

References

Olive V, Bennett M, Walker J, Ma C, Jiang I, Cordon-Cardo C . miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009; 23(24):2839-49. PMC: 2800084. DOI: 10.1101/gad.1861409. View

Pallante P, Terracciano L, Carafa V, Schneider S, Zlobec I, Lugli A . The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer. 2010; 46(12):2304-13. DOI: 10.1016/j.ejca.2010.05.011. View

Zhang X, Zhang L, Qin W, Yao X, Zheng L, Liu X . Oncogenic role of the chromobox protein CBX7 in gastric cancer. J Exp Clin Cancer Res. 2010; 29:114. PMC: 2933612. DOI: 10.1186/1756-9966-29-114. View

Zhang X, Yu H, Lou J, Zheng J, Zhu H, Popescu N . MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem. 2010; 286(2):1429-35. PMC: 3020751. DOI: 10.1074/jbc.M110.146530. View

Hannafon B, Sebastiani P, de las Morenas A, Lu J, Rosenberg C . Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res. 2011; 13(2):R24. PMC: 3219184. DOI: 10.1186/bcr2839. View

Forzati F, Federico A, Pallante P, Abbate A, Esposito F, Malapelle U . CBX7 is a tumor suppressor in mice and humans. J Clin Invest. 2012; 122(2):612-23. PMC: 3266782. DOI: 10.1172/JCI58620. View

Wang F, Li T, Zhang B, Li H, Wu Q, Yang L . MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun. 2013; 434(3):688-94. DOI: 10.1016/j.bbrc.2013.04.010. View

Shinjo K, Yamashita Y, Yamamoto E, Akatsuka S, Uno N, Kamiya A . Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. Int J Cancer. 2013; 135(2):308-18. DOI: 10.1002/ijc.28692. View

Wu Q, Yang Z, An Y, Hu H, Yin J, Zhang P . MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. Cell Death Dis. 2014; 5:e1144. PMC: 3973221. DOI: 10.1038/cddis.2014.110. View

10.

Wang H, Wu S, Zhao L, Zhao J, Liu J, Wang Z . Clinical use of microRNAs as potential non-invasive biomarkers for detecting non-small cell lung cancer: a meta-analysis. Respirology. 2014; 20(1):56-65. DOI: 10.1111/resp.12444. View

11.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

12.

Ben-Hamo R, Efroni S . MicroRNA regulation of molecular pathways as a generic mechanism and as a core disease phenotype. Oncotarget. 2015; 6(3):1594-604. PMC: 4359317. DOI: 10.18632/oncotarget.2734. View

13.

Wang P, Yang D, Zhang H, Wei X, Ma T, Cheng Z . Early Detection of Lung Cancer in Serum by a Panel of MicroRNA Biomarkers. Clin Lung Cancer. 2015; 16(4):313-9.e1. DOI: 10.1016/j.cllc.2014.12.006. View

14.

Sun D, Li X, Ma M, Liu J, Xu Y, Ye L . The predictive value and potential mechanisms of miRNA-328 and miRNA-378 for brain metastases in operable and advanced non-small-cell lung cancer. Jpn J Clin Oncol. 2015; 45(5):464-73. DOI: 10.1093/jjco/hyv009. View

15.

Bruce J, Hui A, Shi W, Perez-Ordonez B, Weinreb I, Xu W . Identification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinoma. Oncotarget. 2015; 6(6):4537-50. PMC: 4414210. DOI: 10.18632/oncotarget.3005. View

16.

Reddy K . MicroRNA (miRNA) in cancer. Cancer Cell Int. 2015; 15:38. PMC: 4424445. DOI: 10.1186/s12935-015-0185-1. View

17.

Li J, Yang S, Yan W, Yang J, Qin Y, Lin X . MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition. Lab Invest. 2015; 95(9):1056-70. DOI: 10.1038/labinvest.2015.76. View

18.

Nishiyama A, Katakami N, Yoshioka H, Iwasaku M, Korogi Y, Hata A . Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer. Lung Cancer. 2015; 89(3):301-5. DOI: 10.1016/j.lungcan.2015.06.017. View

19.

Yang B, Jia L, Guo Q, Ren H, Hu D, Zhou X . MiR-564 functions as a tumor suppressor in human lung cancer by targeting ZIC3. Biochem Biophys Res Commun. 2015; 467(4):690-6. DOI: 10.1016/j.bbrc.2015.10.082. View

20.

Tian L, Shan W, Zhang Y, Lv X, Li X, Wei C . Erratum to: Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer. Pathol Oncol Res. 2015; 22(2):439. DOI: 10.1007/s12253-015-0004-y. View